Scientists at UCL have invented a new test to identify the earliest genetic changes of prostate cancer in blood.
Findings lay the foundation for more personalized treatment
A newly-discovered part of our immune system could be harnessed to treat all cancer, say scientists.
Recently presented data suggests Rubraca may play a meaningful role in the treatment of patients with BRCA 1/2 mutant recurrent, metastatic castrate-resistant prostate cancer.
Scientific report published on February 12, 2020
Read this January 21, 2020 article by a News Reporter-Staff News Editor at Cancer Daily.